½ÃÀ庸°í¼­
»óǰÄÚµå
1540785

¼¼°èÀÇ »ýü Àü±â ÀÇÇÐ ½ÃÀå º¸°í¼­ : À¯Çü, Á¦Ç°, ¿ëµµ, ÃÖÁ¾ ¿ëµµ ¹× Áö¿ªº°(2024-2032³â)

Bioelectric Medicine Market Report by Type, Product, Application, End Use, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 146 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è »ýü Àü±â ÀÇÇÐ ½ÃÀå ±Ô¸ð´Â 2023³â 223¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC ±×·ìÀº 2032³â±îÁö ½ÃÀå ±Ô¸ð°¡ 355¾ï ´Þ·¯¿¡ ´ÞÇϰí, 2024-2032³â°£ 5.15%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

»ýü Àü±â ÀÇÇÐ ¶Ç´Â Àü±â Á¦Á¦¿¡´Â ½Å°æ°èÀÇ Àü±âÀû Àڱذú ½ÅÈ£ Àü´ÞÀ» ÀÌ¿ëÇÏ´Â ÀÇ·á °ü·Ã ±â±â°¡ Æ÷ÇԵ˴ϴÙ. ºÐÀÚ ÀÇÇÐ, ½Å°æ°úÇÐ, »ý¹°°øÇÐÀ» °áÇÕÇÏ¿© Áúº´ Ä¡·á Áß »ý¹°ÇÐÀû °úÁ¤À» À§ÇÑ ½Å°æ ÀÚ±Ø ±â¼úÀ» °³¹ßÇÕ´Ï´Ù. Àΰø¿Í¿ì, ¸Á¸· À̽Ä, ¸±¸®ÇÁ, ½ÉÀå ¹Úµ¿±â, ô¼ö Àڱرâ, À̽ÄÇü Á¦¼¼µ¿±â µîÀ¸·Î ±¸¼ºµË´Ï´Ù. »ýü Àü±â ÀÇÇп¡´Â ·ù¸¶Æ¼½º °üÀý¿°, ¿°Áõ¼º Àå Áúȯ, ¾Ï, ºñ¸¸, ´ç´¢º´, õ½Ä, ¸¶ºñ, ½ÉÇ÷°ü Áúȯ(CVD) µî ´Ù¾çÇÑ ¸¸¼º ÁúȯÀ» Áø´ÜÇϰí Ä¡·áÇÒ ¼ö ÀÖ´Â ÃʼÒÇü ÀüÀÚ ÀÓÇöõÆ®°¡ Æ÷ÇԵ˴ϴÙ. ºñħ½ÀÀû Á¢±Ù¹ý°ú ħ½ÀÀû Á¢±Ù¹ýÀ» ÅëÇØ ´Ù¾çÇÑ Áõ»ó°ú Àå¾Ö¸¦ Ä¡·áÇÒ ¼ö ÀÖ½À´Ï´Ù.

»ýü Àü±â ÀÇÇÐ ½ÃÀå µ¿Çâ :

³ëÀÎ Àα¸ Áõ°¡¿Í Àü ¼¼°è ½ÉÇ÷°ü Áúȯ ¹× ½Å°æ Áúȯ Áõ°¡·Î ÀÎÇØ ½ÃÀå Àü¸ÁÀº ¹à½À´Ï´Ù. »ýü Àü±â ÀÇÇд ³ú½ÉºÎÀڱرâ, ¹ÌÁֽŰæ õ°ñ Àڱرâ, °æÇÇÀû Àü±â ½Å°æ Àڱر⸦ »ç¿ëÇÏ¿© ÀÌ·¯ÇÑ ÁúȯÀ» Ä¡·áÇÕ´Ï´Ù. ÀÌ¿Í ÇÔ²² À̽ÄÇü Á¦¼¼µ¿±â¿Í ½ÉÀå ¹Úµ¿±â¸¦ »ç¿ëÇÏ¿© Áúº´À» Ä¡·áÇÏ´Â ºÎÁ¤¸ÆÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ ¶ÇÇÑ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÆÄŲ½¼º´°ú ¿ì¿ïÁõ, ºñ¸¸°ú °°Àº »ýȰ½À°üº´À¸·Î ÀÎÇÑ Àå¾Ö Áõ°¡·Î ÀÎÇÑ ³ú½ÉºÎÀڱر⿡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î Á¦Á¶¾÷üµéÀº ºÎÁ¤¸ÆÀ» Á¶±â¿¡ ¹ß°ßÇϰí Áø´ÜÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â ½º¸¶Æ® Á¦Ç°À» Ãâ½ÃÇÏ¿© ¼ÒºñÀÚÀÇ ¹ÌÃæÁ· ¼ö¿ä¸¦ ÃæÁ·½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÷´Ü »ýü Àü±â ÀÇÇп¡ ´ëÇÑ ½ÂÀÎ Áõ°¡¿Í »õ·Î¿î Ä¡·á¹ý ¹× Àü±â Á¦Á¦¿¡ ´ëÇÑ ÅõÀÚ ¹× ÀÚ±Ý Á¶´Þ Áõ°¡´Â ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ ±¤¹üÀ§ÇÑ Á¶»ç °³¹ß(R&D) Ȱµ¿, ÀÇ·á ÀÎÇÁ¶óÀÇ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå, ¼ÒºñÀÚÀÇ ÁöÃâ ´É·Â Áõ°¡, Ä¡·á ¸ñÀûÀÇ Ã·´Ü ÀÇ·á±â±âÀÇ Á¸Àç°¡ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®µé

  • ¼¼°è »ýü Àü±â ÀÇÇÐ ½ÃÀå ±Ô¸ð´Â?
  • 2024-2032³â ¼¼°è »ýü Àü±â ÀÇÇÐ ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¼¼°è »ýü Àü±â ÀÇÇÐ ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀº?
  • Äڷγª19°¡ ¼¼°è »ýü Àü±â ÀÇÇÐ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ¼¼°è »ýü Àü±â ÀÇÇÐ ½ÃÀåÀÇ À¯Çüº° ºÐ·ù´Â?
  • ¼¼°è »ýü Àü±â ÀÇÇÐ ½ÃÀåÀÇ Á¦Ç°º° ½ÃÀå ÇöȲÀº?
  • ¼¼°è »ýü Àü±â ÀÇÇÐ ½ÃÀåÀÇ ¿ëµµº° ½ÃÀå ÇöȲÀº?
  • »ýü Àü±â ÀÇÇÐ ½ÃÀåÀÇ ¿ëµµº° ºÐ·ù´Â?
  • ¼¼°è »ýü Àü±â ÀÇÇÐ ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°è »ýü Àü±â ÀÇÇÐ ½ÃÀåÀÇ ÁÖ¿ä ÁøÃâ ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ Á¢±Ù
    • Åé´Ù¿î Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ »ýü Àü±â ÀÇÇÐ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ºÐ¼®
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ºÐ¼® : À¯Çüº°

  • À̽ÄÇü Àü±â ¾à¸®ÇÐÀû Àåºñ
  • ºñħ½À¼º Àü±â ¾à¸®ÇÐÀû Àåºñ

Á¦7Àå ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • À̽ÄÇü Á¦¼¼µ¿±â
  • ½ÉÀå ÆäÀ̽º¸ÞÀÌÄ¿
  • Àΰø¿Í¿ì
  • ô¼ö Àڱرâ
  • ³ú½ÉºÎ Àڱرâ
  • °æÇÇÀû Àü±â ½Å°æ Àڱرâ
  • õ°ñ½Å°æ Àڱرâ
  • ¹ÌÁֽŰæ Àڱرâ
  • ±âŸ

Á¦8Àå ½ÃÀå ºÐ¼® : ¿ëµµº°

  • ºÎÁ¤¸Æ
  • ÅëÁõ °ü¸®
  • °¨À½ ³­Ã»
  • ÆÄŲ½¼º´
  • Èçµé·Á¶ó
  • ¿ì¿ïÁõ
  • Ä¡·á ÀúÇ×¼º ¿ì¿ïÁõ
  • °£Áú
  • ¿ä½Ç±Ý ¹× º¯½Ç±Ý
  • ±âŸ

Á¦9Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾ ¿ëµµº°

  • º´¿ø
  • ¿¬±¸±â°ü
  • °³ÀÎ »ç¿ëÀÚ
  • ±âŸ

Á¦10Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦11Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå PorterÀÇ Five Forces ºÐ¼®

  • °³¿ä
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Abbott Laboratories
    • Biotronik SE & Co KG
    • Boston Scientific Corporation
    • Cochlear Limited
    • electroCore Inc.
    • LivaNova PLC
    • MED-EL Medical Electronics
    • Medtronic plc
    • Sonova Holding AG
LSH 24.09.02

The global bioelectric medicine market size reached US$ 22.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 35.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5.15% during 2024-2032.

Bioelectric medicine or electroceuticals encompasses medical-related devices that utilize electrical impulses and signaling in the nervous system. It combines molecular medicine, neuroscience, and bioengineering to develop nerve-stimulating technologies for biological processes during the treatment of diseases. It consists of cochlear, retinal implants, relief, cardiac pacemakers, spinal cord stimulators, and implantable defibrillators. Bioelectric medicine includes tiny electronic implants that can diagnose and treat various chronic diseases, such as rheumatoid arthritis, inflammatory bowel disease, cancer, obesity, diabetes, asthma, paralysis, and cardiovascular diseases (CVDs). It can treat a wide range of conditions and disorders using both non-invasive and invasive approaches.

Bioelectric Medicine Market Trends:

The growing geriatric population and the increasing incidences of cardiovascular and neurological disorders across the globe are creating a positive outlook for the market. Bioelectric medicine uses the deep brain, vagus sacral, and transcutaneous electric nerve stimulator to treat these conditions. In line with this, the escalating prevalence of arrhythmia that involves the use of implantable cardioverter-defibrillators and cardiac pacemakers to treat the ailment is acting as another growth-inducing factor. Additionally, the increasing demand for deep brain stimulators owing to the rising instances of Parkinson's disease and lifestyle-induced disorders, such as depression and obesity, is favoring the market growth. Apart from this, manufacturers are launching smart products that help in the early detection and diagnosis of cardiac arrhythmias and cater unmet needs of the consumers, which, in turn, is providing an impetus to the market growth. Moreover, increasing approvals for advanced bioelectric medicine and a rise in investment and funding of new therapies and electroceuticals are positively influencing the market growth. Besides this, extensive research and development (R&D) activities, significant growth in the healthcare infrastructure, increasing expenditure capacities of consumers, and the presence of advanced medical devices for treatment purposes are supporting the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global bioelectric medicine market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, product, application and end use.

Breakup by Type:

Implantable Electroceutical Devices

Non-Invasive Electroceutical Devices

Breakup by Product:

Implantable Cardioverter Defibrillators

Cardiac Pacemakers

Cochlear Implants

Spinal Cord Stimulators

Deep Brain Stimulators

Transcutaneous Electrical Nerve Stimulators

Sacral Nerve Stimulators

Vagus Nerve Stimulators

Others

Breakup by Application:

Arrhythmia

Pain Management

Sensorineural Hearing Loss

Parkinson's Disease

Tremor

Depression

Treatment-Resistant Depression

Epilepsy

Urinary and Fecal Incontinence

Others

Breakup by End Use:

Hospitals

Research Institutes

Individual Users

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Biotronik SE & Co KG, Boston Scientific Corporation, Cochlear Limited, electroCore Inc., LivaNova PLC, MED-EL Medical Electronics, Medtronic plc and Sonova Holding AG.

Key Questions Answered in This Report

  • 1. How big is the global bioelectric medicine market?
  • 2. What is the expected growth rate of the global bioelectric medicine market during 2024-2032?
  • 3. What are the key factors driving the global bioelectric medicine market?
  • 4. What has been the impact of COVID-19 on the global bioelectric medicine market?
  • 5. What is the breakup of the global bioelectric medicine market based on the type?
  • 6. What is the breakup of the global bioelectric medicine market based on the product?
  • 7. What is the breakup of the global bioelectric medicine market based on the application?
  • 8. What is the breakup of the global bioelectric medicine market based on the end use?
  • 9. What are the key regions in the global bioelectric medicine market?
  • 10. Who are the key players/companies in the global bioelectric medicine market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Bioelectric Medicine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Implantable Electroceutical Devices
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Non-Invasive Electroceutical Devices
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Implantable Cardioverter Defibrillators
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cardiac Pacemakers
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cochlear Implants
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Spinal Cord Stimulators
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Deep Brain Stimulators
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Transcutaneous Electrical Nerve Stimulators
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Sacral Nerve Stimulators
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast
  • 7.8 Vagus Nerve Stimulators
    • 7.8.1 Market Trends
    • 7.8.2 Market Forecast
  • 7.9 Others
    • 7.9.1 Market Trends
    • 7.9.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Arrhythmia
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pain Management
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Sensorineural Hearing Loss
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Parkinson's Disease
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Tremor
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Depression
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Treatment-Resistant Depression
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast
  • 8.8 Epilepsy
    • 8.8.1 Market Trends
    • 8.8.2 Market Forecast
  • 8.9 Urinary and Fecal Incontinence
    • 8.9.1 Market Trends
    • 8.9.2 Market Forecast
  • 8.10 Others
    • 8.10.1 Market Trends
    • 8.10.2 Market Forecast

9 Market Breakup by End Use

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Research Institutes
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Individual Users
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Biotronik SE & Co KG
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Boston Scientific Corporation
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Cochlear Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 electroCore Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 LivaNova PLC
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 MED-EL Medical Electronics
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 Medtronic plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Sonova Holding AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦